Degarelix: 6 agencies, 2009–2023
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 14.2 years separate the first record, 23 Sep 2009 at HAS (France), from the most recent, 11 Dec 2023 at SMC (Scotland).
TLV (Sweden) changed its position: not recommended on 30 Apr 2012, restricted by 1 Dec 2017, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
4 distinct indication wordings are recorded for degarelix by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess degarelix, on 23 Sep 2009; PBAC (Australia) did not open a file until 2017 — a wide spread of 7.8 years between the earliest and latest system to look at it.
3 of the 6 agencies here assessed degarelix more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for degarelix.
The full ledger for degarelix reads 6 recommended, 2 restricted, 2 not recommended and 1 superseded, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 11 Dec 2023 | for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy as neo-adjuvant treatment prior to radiothera… | accepted | source |
| TLV (Sweden) | 1 Dec 2017 | Firmagon ingår i högkostnadsskyddet med begränsad subvention | restricted subsidy | source |
| PBAC (Australia) | 2017 | Locally advanced (equivalent to stage C) or metastatic (equivalent to stage D) carcinoma of the prostate | The PBAC recommended amending the listing of degarelix from Authority Required (STREAMLINE… | source |
| NICE (England) | 24 Aug 2016 | NICE TA404 | recommended (optimised) | source |
| HAS (France) | 23 Sep 2009 | Listing (Transparency Committee) | ASMR V | source |
7 further decisions for degarelix, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- enzalutamide — same ATC class L02B — Endocrine therapy
- darolutamide — same ATC class L02B — Endocrine therapy
- apalutamide — same ATC class L02B — Endocrine therapy
- abiraterone — same ATC class L02B — Endocrine therapy
- fulvestrant — same ATC class L02B — Endocrine therapy
- relugolix — same ATC class L02B — Endocrine therapy
Coverage: 12 decisions for degarelix from 6 agencies, 2009 to 2023. Data to 7 Sep 2026. ATC class L02B — Endocrine therapy. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.